Interferon alfa treatment for Sjogren's syndrome associated neuropathy
نویسندگان
چکیده
منابع مشابه
Interferon alfa treatment for Sjogren's syndrome associated neuropathy.
Treatment response to interferon alfa (IFNalpha) is described in three consecutive cases of two forms of Sjogren's syndrome associated neuropathy (SSN)-two with sensory ataxic ganglionopathy and one with sensorimotor neuropathy with demyelinating features. All responded well to IFNalpha in terms of neuropathic symptoms, sicca symptoms, antibody titres, and findings in salivary gland biopsy spec...
متن کاملLymphoblastoid interferon alfa treatment in chronic hepatitis
Interferon is becoming the standard treatment in adults for chronic hepatitis C. Twenty one children with histologically proved chronic hepatitis C (10 boys, range 2 5-13 years), who were otherwise healthy, were enrolled in a randomised controlled study to test their response to interferon alfa. Eleven children were treated with lymphoblastoid interferon alfa (3 million units/M2) for 12 months;...
متن کاملLow-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement.
A 68-year-old man presented with a medical history of recurrent bronchial asthma and sinusitis maxillaris. He had a severe bronchial infection that was treated with a combinationproductofsulfamethoxazoleandtrimethoprimand subsequentlywithcefadroxil incombinationwith low-dose (20 mg/d of prednisolone) therapy for treatment of the asthma. Three weeks after discontinuation of of antibiotic therapy...
متن کاملInterferon alfa therapy: toward an improved treatment for HIV infection.
Highly active antiretroviral therapy (HAART) is an expensive, lifelong treatment for human immunodeficiency virus (HIV) infection that is associated with significant toxicity. Despite advances in treatment, there remains a need for novel therapies for HIV infection. One strategy is to achieve a functional cure, in which treatment can be safely stopped despite the presence of residual virus, by ...
متن کاملA new treatment for polycythemia vera: recombinant interferon alfa.
Recombinant interferon alfa, a natural product with growth inhibitory capabilities, has been demonstrated for the first time to have significant therapeutic efficacy in controlling the red cell mass in patients with the myeloproliferative disease polycythemia vera. The starting dose was 3.0 X 10(6) U three times a week, subcutaneously (SC). In three patients the dose required was 5.0 X 10(6), U...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry
سال: 2005
ISSN: 0022-3050
DOI: 10.1136/jnnp.2004.049502